Loading
A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.
MammaPrint is Agendia's 70-gene signature. MINDACT (n=6,693): women with high clinical but low genomic risk had 5-year distant metastasis-free survival of 94.7% without chemotherapy; 8-year update showed a small benefit of chemotherapy in women under 50. FDA-cleared (2007), NCCN-listed alongside Oncotype DX; BluePrint adds molecular subtyping. Also used to identify 'ultralow' risk tumours with indolent behaviour.
Microarray or NGS expression of 70 genes → dichotomous low/high risk.
1.MammaPrint (70-gene signature) slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 2007 | FDA 510(k) clearance for recurrence risk in early breast cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MammaPrint" OR ABSTRACT:"MammaPrint" OR TITLE:"70-gene signature" OR ABSTRACT:"70-gene signature") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MammaPrint (70-gene signature), not a curated reading list.
Shares Gene-expression assay → chemotherapy omission, Gene-expression prognostic assays, Enrichment and biomarker-stratified designs, Oncotype DX.
Shares TAILORx, Oncotype DX, Companion diagnostics, HR-positive / HER2-negative breast cancer.
Shares Prosigna (PAM50), Oncotype DX, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares TAILORx, Oncotype DX.
Shares High-risk early HR-positive breast cancer, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, HR-positive / HER2-negative breast cancer.